Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study.

ABSTRACT:

Background

Level I evidence supports the use of sorafenib in patients with Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma, where heterogeneity in efficacy exists due to varying clinicopathologic features of the disease.

Aim

We evaluated whether prior treatment with curative or locoregional therapies influences sorafenib-specific survival.

Methods

From a prospective data set of 785 consecutive patients from international specialist centres, 264 patients (34%) were treatment naïve (TN) and 521 (66%) were pre-treated (PT), most frequently with transarterial chemoembolization (n = 413; 79%). The primary endpoint was overall survival (OS) from sorafenib initiation with prognostic factors tested on uni- and multivariate analyses.

Results

SUBMITTER: Yen C 

PROVIDER: S-EPMC5704701 | biostudies-literature | 2017 Nov

REPOSITORIES: biostudies-literature